Zimmer Biomet Holdings, Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Thu, August 6, 2026 at 12:01 AM GMT+3 4 min read

Zimmer Biomet Holdings, Inc. Q2 2026 Earnings Call Summary - Moby

Strategic Execution and Commercial Transformation

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Delivered 4% organic constant currency growth, led by a 4.6% increase in the U.S. market as the sales force specialization strategy yields higher productivity and lower-than-expected attrition.
Hip performance was driven by the 'triple play' strategy, with the Z1 triple-taper hip stem now representing over 40% of U.S. stems and AI-based navigation adoption accelerating.
International growth of 3.1% was bolstered by the 'first-to-the-world' iodine-coated hip launch in Japan, which is capturing competitive share and commanding a 40% price premium.
Technology and Data sales surged 53% in the U.S., reflecting a healthy capital expenditure environment and surgeon enthusiasm for the comprehensive ROSA robotic suite.
The Paragon 28 integration is serving as a template for future M&A, maintaining mid-teens growth with negligible turnover among key personnel post-acquisition.
Operational excellence initiatives are shifting R&D to a new global capability center in India and expanding manufacturing to Costa Rica to improve long-term cost structures.
Management attributes the U.S. Knee growth of 1.4% to temporary market noise and remains confident in a stable underlying market growth rate of 4% to 5%.

2026 Outlook and Long-Term Growth Framework

Raised full-year organic constant currency revenue guidance to 2.25%-3.25% based on strong first-half momentum and successful commercial channel transitions.
Increased adjusted EPS guidance to $8.47-$8.59, incorporating a $250 million increase in planned share repurchases for a total of $1 billion in 2026.
Anticipate the introduction of over 50 new products in the next 36 months, focusing on 'first-to-the-world' technologies to reach a 5% to 6% weighted average market growth rate by 2030.
The U.S. sales force transition is scheduled for completion by the end of 2027, which management expects will create a more durable and scalable growth engine.
Guidance assumes a healthy orthopedic procedural market and stable pricing erosion of up to 100 basis points, despite potential macro and regulatory headwinds.

Market Dynamics and Risk Factors

China remains a headwind, declining 20% in the period and impacting international knee performance, though it now represents only 2% of total company revenue.
Operating margins are expected to decline slightly more than 50 basis points for the full year due to intentional, front-loaded investments in the U.S. commercial organization.
Exposure to ACA and Medicaid exchange subsidies is characterized as low single-digit, with the vast majority of the payer mix tied to stable Medicare and commercial segments.
Trauma and restorative therapies continue to be identified as pressure points within the S.E.T. segment, necessitating ongoing operational adjustments.

Q&A Session Highlights

Sustainability of SG&A investments and sales force transition progress

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management characterized the increased SG&A as a deliberate 'growth strategy' rather than a cost-saving measure, focusing on retention and recruiting top med-tech talent.
The transition is in its second of three stages, with the most significant risk of customer disruption already appearing lower than initially modeled.

Impact of potential ACA subsidy expirations on procedure volumes

Management dismissed concerns regarding ACA impacts, noting that the average hip/knee patient is 65-67 years old and primarily covered by Medicare.
Internal data shows surgical waiting lists at top hospitals remain steady at 3 to 6 months, with patient cancellation rates remaining low in the teens.

Strategic rationale for maintaining multiple robotic and tech platforms

The company aims to be a 'technology company' rather than just a robotic one, offering options for the 80% of surgeons who do not currently use large-footprint robots.
Management indicated they may 'prune the portfolio' in the future as standard-of-care winners emerge, but currently value the optionality of cordless and imageless solutions.

M&A priorities and financial criteria for future deals

Future targets will focus on high-growth Recon segments, S.E.T. verticals, and adjacent ASC-focused procedures with a typical deal size up to $2 billion.
Financial guardrails require deals to be revenue-accretive immediately, EPS-accretive by year two, and deliver double-digit ROIC by year five.